PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32276266-7 2020 Additionally, genistein dramatically decreased epidermal growth factor receptor (EGFR) expression and attenuated its down-stream signaling molecules STAT3, MDM2, Akt and JAK1/2 phosphorylation, resulting in inhibited nuclear translocation of STAT3 and MDM2, thereby inhibiting the JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways. Genistein 14-23 tumor protein p53 Homo sapiens 307-310 32276266-0 2020 Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways. Genistein 57-66 tumor protein p53 Homo sapiens 112-115 32705888-8 2021 Genistein increased the expression levels of p53 and p21 with decreased phosphorylated p21, but did not affect the levels of major cyclin-CDK complexes. Genistein 0-9 tumor protein p53 Homo sapiens 45-48 32276266-10 2020 Taken together, genistein suppressed the JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways by decreasing EGFR expression, leading to cell apoptosis, cell cycle arrest, and proliferation inhibition in EsC cells. Genistein 16-25 tumor protein p53 Homo sapiens 67-70 29990856-4 2018 In addition, we also observed that tumor suppressor p53 was increased under genistein treatment. Genistein 76-85 tumor protein p53 Homo sapiens 52-55 31538075-7 2019 In the CaSki cells, the p-ERK1/2 level decreased by 37%, the p53 expression level increased by 304%, and the cleaved caspase 3 level increased by 115% in the cisplatin+genistein group compared to that in the cisplatin group. Genistein 168-177 tumor protein p53 Homo sapiens 61-64 30737644-0 2019 ERbeta modulates genistein"s cisplatin-enhancing activities in breast cancer MDA-MB-231 cells via P53-independent pathway. Genistein 17-26 tumor protein p53 Homo sapiens 98-101 29990856-6 2018 Therefore, our findings suggest that genistein can suppress laryngeal cancer cell survival through p53 -miR-1469-Mcl1pathway. Genistein 37-46 tumor protein p53 Homo sapiens 99-102 27861885-7 2017 TP53-depeleted LNCaP and NCI-H460 cells using shRNA targeting human TP53 were more sensitive to cell death by treatment of genistein. Genistein 123-132 tumor protein p53 Homo sapiens 0-4 27861885-7 2017 TP53-depeleted LNCaP and NCI-H460 cells using shRNA targeting human TP53 were more sensitive to cell death by treatment of genistein. Genistein 123-132 tumor protein p53 Homo sapiens 68-72 27861885-9 2017 These data suggest that genistein may be a promising anticancer drug candidate due to its inhibitory activity against Plk1 as well as EGFR and effectiveness toward cancer cells, especially those with p53-mutation. Genistein 24-33 tumor protein p53 Homo sapiens 200-203 26768552-0 2016 The enhancing effect of genistein on apoptosis induced by trichostatin A in lung cancer cells with wild type p53 genes is associated with upregulation of histone acetyltransferase. Genistein 24-33 tumor protein p53 Homo sapiens 109-112 29282909-6 2016 The expressions of PSA, Cyclin D1, and PCNA were gradually down-regulated while that of P53 up-regulated with the increased concentration of GEN (P<0.05). Genistein 141-144 tumor protein p53 Homo sapiens 88-91 26768552-5 2016 We found that the enhancing effect of genistein on cell-growth-arrest in ABC-1 cells (p53 mutant) was less than in A549 and H460 cells. Genistein 38-47 tumor protein p53 Homo sapiens 86-89 26768552-7 2016 After silencing p53 expression in A549 and H460 cells, the enhancing effect of genistein was diminished. Genistein 79-88 tumor protein p53 Homo sapiens 16-19 26768552-10 2016 The inhibitor of acetyltransferase, anacardic acid, diminished the enhancing effect of genistein on all TSA-induced histone/p53 acetylation and apoptosis. Genistein 87-96 tumor protein p53 Homo sapiens 124-127 26768552-13 2016 Taken together, these results suggest that the enhancing effects of genistein on TSA-induced apoptosis in lung cancer cells were p53-dependent and were associated with histone/non-histone protein acetylation. Genistein 68-77 tumor protein p53 Homo sapiens 129-132 26469967-5 2015 to show that genistein, a major component of isoflavone that is known to have anti-tumor activities in a variety of models, induces Bax/p53-independent cell death in HCT116 Bax knockout (KO), HCT116 p53 KO, DU145 Bax KO, or DU145 p53 KO cells that express wild-type (WT) Bak. Genistein 13-22 tumor protein p53 Homo sapiens 136-139 26469967-5 2015 to show that genistein, a major component of isoflavone that is known to have anti-tumor activities in a variety of models, induces Bax/p53-independent cell death in HCT116 Bax knockout (KO), HCT116 p53 KO, DU145 Bax KO, or DU145 p53 KO cells that express wild-type (WT) Bak. Genistein 13-22 tumor protein p53 Homo sapiens 199-202 26469967-13 2015 Our results also suggest that genistein may be an effective agent for overcoming chemoresistance in cancers with dysfunctional Bax and p53. Genistein 30-39 tumor protein p53 Homo sapiens 135-138 26469967-5 2015 to show that genistein, a major component of isoflavone that is known to have anti-tumor activities in a variety of models, induces Bax/p53-independent cell death in HCT116 Bax knockout (KO), HCT116 p53 KO, DU145 Bax KO, or DU145 p53 KO cells that express wild-type (WT) Bak. Genistein 13-22 tumor protein p53 Homo sapiens 199-202 23686257-0 2013 Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells. Genistein 0-9 tumor protein p53 Homo sapiens 63-66 26032169-0 2015 Genistein induces apoptosis by stabilizing intracellular p53 protein through an APE1-mediated pathway. Genistein 0-9 tumor protein p53 Homo sapiens 57-60 26032169-4 2015 We initially showed that the p53 protein level was elevated in GEN-treated human non-small lung cancer A549 cells and cervical cancer HeLa cells. Genistein 63-66 tumor protein p53 Homo sapiens 29-32 25745770-15 2014 The aim of the study was to investigate genistein as a potential inhibitor of CTGF and TGFbeta1, beta2 and beta3 isoforms expression and a potential regulator of p53. Genistein 40-49 tumor protein p53 Homo sapiens 162-165 23686257-11 2013 In addition, genistein caused cell cycle arrest in the G2/M phase, which was accompanied by activation of ATM/p53, p21waf1/cip1 and GADD45alpha as well as downregulation of cdc2 and cdc25A demonstrated by q-PCR and immunoblotting assay. Genistein 13-22 tumor protein p53 Homo sapiens 110-113 23686257-12 2013 Interestingly, genistein induced G2/M cell cycle arrest in a p53-dependent manner. Genistein 15-24 tumor protein p53 Homo sapiens 61-64 23686257-14 2013 The ATM/p53-p21 cross-regulatory network may play a crucial role in mediating the anticarcinogenic activities of genistein in colon cancer. Genistein 113-122 tumor protein p53 Homo sapiens 8-11 23351311-16 2012 Appropriate timing of administration and concentration of genistein determine the outcome of treatment and this method could potentially be developed as an alternative strategy for treatment of p53 defective cancer cells. Genistein 58-67 tumor protein p53 Homo sapiens 194-197 23351311-0 2012 Genistein abrogates G2 arrest induced by curcumin in p53 deficient T47D cells. Genistein 0-9 tumor protein p53 Homo sapiens 53-56 22736505-3 2012 Here, we demonstrate that genistein inhibits the growth of glioblastoma multiforme and medulloblastoma cells with different TP53 mutations and radio-responses by arresting the cells at G2/M phase of the cell cycle. Genistein 26-35 tumor protein p53 Homo sapiens 124-128 22960751-3 2012 In the present study, our results showed that genistein, an element found in soy, is an epigenetic modifier able to decrease hypermethylation levels of CHD5, and enhances the expression of CHD5 as well as p53, possibly contributing to inhibition of NB growth in vivo and tumor microvessel formation. Genistein 58-67 tumor protein p53 Homo sapiens 241-244 19777160-0 2010 Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification. Genistein 38-47 tumor protein p53 Homo sapiens 169-172 21965740-9 2011 Genistein and quercetin induced extrinsic apoptosis pathway, up-regulating p53. Genistein 0-9 tumor protein p53 Homo sapiens 75-78 18431742-3 2008 We tested the hypothesis that genistein activates expression of several aberrantly silenced tumor suppressor genes (TSGs) that have unmethylated promoters such as PTEN, CYLD, p53 and FOXO3a. Genistein 30-39 tumor protein p53 Homo sapiens 175-178 19994890-10 2010 Western blot data revealed that genistein (6) stimulated an increase in the protein expression of Fas, FasL, and p53. Genistein 32-41 tumor protein p53 Homo sapiens 113-116 20661829-0 2010 Protection of p53 wild type cells from taxol by genistein in the combined treatment of lung cancer. Genistein 48-57 tumor protein p53 Homo sapiens 14-17 18716605-4 2008 Genistein also decreased cisplatin-induced apoptosis by regulating p53 induction in kidney. Genistein 0-9 tumor protein p53 Homo sapiens 67-70 18847459-11 2008 Furthermore, genistein induced the expression of apoptotic and anti-migratory proteins p53 and p38 in all cell lines. Genistein 13-22 tumor protein p53 Homo sapiens 87-90 20554748-7 2010 Our findings provide support to GEN-induced PTEN as both a target and regulator of p53 action and offer a mechanistic basis for PTEN pathway activation to underlie the antitumor properties of dietary factors, with important implications for reducing breast cancer risk. Genistein 32-35 tumor protein p53 Homo sapiens 83-86 20446899-2 2010 This study suggested that G2/M cell cycle arrest was triggered by ROS/NO productions with regulations of p53, p21, cell division cycle 25C (Cdc25C), Cdc2 and cyclin B1, which were able to be prevented by protein tyrosine kinase (PTK) activity inhibitor genistein or JNK inhibitor SP600125. Genistein 253-262 tumor protein p53 Homo sapiens 105-108 19732843-7 2009 Moreover, genistein enhances the phosphorylation and activation of p53, while decreases the ratio of Bcl-2/Bax and Bcl-xL/Bax and the level of phosphorylated Akt, which result in cells undergoing apoptosis. Genistein 10-19 tumor protein p53 Homo sapiens 67-70 19373614-2 2009 Here we report two chemopreventive agents, selenite and genistein, that have synergistic effects on apoptosis, cell cycle arrest, and associated signaling pathways in p53-expressing LNCaP and p53-null PC3 prostate cancer cells. Genistein 56-65 tumor protein p53 Homo sapiens 167-170 19373614-2 2009 Here we report two chemopreventive agents, selenite and genistein, that have synergistic effects on apoptosis, cell cycle arrest, and associated signaling pathways in p53-expressing LNCaP and p53-null PC3 prostate cancer cells. Genistein 56-65 tumor protein p53 Homo sapiens 192-195 18357397-9 2008 There was an increase in the p53 and p21 levels in response to genistein. Genistein 63-72 tumor protein p53 Homo sapiens 29-32 18357397-13 2008 Moreover, the ectopic expression of temperature-sensitive p53V135A, which acts as a dominant-negative p53 mutant at 38.5 degrees C but assumes p53 wild-type properties at 32.5 degrees C, in LN-18 or LNT-229 cells, had no effect on genistein cytotoxicity at either temperature. Genistein 231-240 tumor protein p53 Homo sapiens 58-61 17404287-0 2007 A critical role for p53 in the control of NF-kappaB-dependent gene expression in TLR4-stimulated dendritic cells exposed to Genistein. Genistein 124-133 tumor protein p53 Homo sapiens 20-23 17727682-7 2007 In addition, treatment with 30 microM genistein strongly induced phosphorylation of checkpoint kinase (CHK) 2 and p53 at serines 15, 20 and 37. Genistein 38-47 tumor protein p53 Homo sapiens 114-117 17727682-8 2007 Caffeine, an inhibitor of ataxia-telangiectasia mutated protein kinase, alleviated the genistein-induced p53 and CHK2 phosphorylation, suggesting the involvement of DNA damage at 30 microM. Genistein 87-96 tumor protein p53 Homo sapiens 105-108 18324703-2 2008 Using analysis of proteins related to cell cycle and apoptotic pathways, we confirmed an elevated level of p53 accompanying p21 Waf1/Cip1 protein in genistein-treated or genistin-treated A549 and WI-38 cells, but not in HeLa cells. Genistein 149-158 tumor protein p53 Homo sapiens 107-110 18324703-3 2008 In addition, a p53-upregulated modulator of apoptosis (Puma) protein accumulated significantly in genistein-treated A549 and WI-38 cells, but not in genistin-treated or beta-estradiol-treated cells, though the growth of any ingredient-treated cells was severely inhibited. Genistein 98-107 tumor protein p53 Homo sapiens 15-18 18324703-4 2008 Intriguingly, the caspase-3 activity of genistein-treated A549 cells, in which Puma or p53 expression was knocked-down by RNA interference (RNAi), remained unaltered compared to that in cells transfected with irrelevant RNAi. Genistein 40-49 tumor protein p53 Homo sapiens 87-90 17404287-9 2007 Moreover, analysis of IL-6 mRNA levels in bone marrow-derived p53 null vs wild-type dendritic cells confirms a role for p53 in the reduction of NF-kappaB-dependent gene expression, mediated by genistein. Genistein 193-202 tumor protein p53 Homo sapiens 120-123 17406801-10 2007 Incubation of nonfunctional TP53 cells with genistein or estradiol increased radiosensitivity in both tested concentrations. Genistein 44-53 tumor protein p53 Homo sapiens 28-32 17406801-13 2007 CONCLUSION: NSCLC cells with nonfunctional TP53 might be sensitized against radiation by genistein or estradiol. Genistein 89-98 tumor protein p53 Homo sapiens 43-47 15177039-0 2004 The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. Genistein 18-27 tumor protein p53 Homo sapiens 149-152 15896711-7 2005 These appear to be followed by the specific activation of AMPK and the up-regulation of p53, p21, and Bax by genistein. Genistein 109-118 tumor protein p53 Homo sapiens 88-91 15659824-9 2004 In the presence of estrogen, p21 and p53 protein expression were upregulated by high concentrations of genistein. Genistein 103-112 tumor protein p53 Homo sapiens 37-40 15177039-3 2004 We previously showed that genistein, a naturally occurring isoflavonoid, induced increased ATM protein kinase activity, ATM-dependent phosphorylation of p53 on serine 15 and activation of the DNA-binding properties of p53. Genistein 26-35 tumor protein p53 Homo sapiens 153-156 11316564-6 2001 In terms of changes in expression of p53-related proteins, increase in expression of Bax and decrease in that of Bcl-2 were observed in TE-2 but not in TE-1, suggesting that the main mode of cell death induced by genistein in a cell line with wild type p53 differed from that with mutant p53. Genistein 213-222 tumor protein p53 Homo sapiens 37-40 15177039-3 2004 We previously showed that genistein, a naturally occurring isoflavonoid, induced increased ATM protein kinase activity, ATM-dependent phosphorylation of p53 on serine 15 and activation of the DNA-binding properties of p53. Genistein 26-35 tumor protein p53 Homo sapiens 218-221 15177039-4 2004 Here, we show that genistein also induces phosphorylation of p53 at serines 6, 9, 20, 46, and 392, and that genistein-induced accumulation and phosphorylation of p53 is reduced in two ATM-deficient human cell lines. Genistein 19-28 tumor protein p53 Homo sapiens 61-64 15177039-4 2004 Here, we show that genistein also induces phosphorylation of p53 at serines 6, 9, 20, 46, and 392, and that genistein-induced accumulation and phosphorylation of p53 is reduced in two ATM-deficient human cell lines. Genistein 19-28 tumor protein p53 Homo sapiens 162-165 15177039-4 2004 Here, we show that genistein also induces phosphorylation of p53 at serines 6, 9, 20, 46, and 392, and that genistein-induced accumulation and phosphorylation of p53 is reduced in two ATM-deficient human cell lines. Genistein 108-117 tumor protein p53 Homo sapiens 61-64 15177039-4 2004 Here, we show that genistein also induces phosphorylation of p53 at serines 6, 9, 20, 46, and 392, and that genistein-induced accumulation and phosphorylation of p53 is reduced in two ATM-deficient human cell lines. Genistein 108-117 tumor protein p53 Homo sapiens 162-165 14757171-6 2004 Genistein enhanced the activity of the checkpoint kinase, Chk2, which phosphorylates/inactivates Cdc25C, induced accumulation of p53, and activated the ataxia-telangiectasia-mutated (ATM) gene. Genistein 0-9 tumor protein p53 Homo sapiens 129-132 12767058-0 2003 Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Genistein 73-82 tumor protein p53 Homo sapiens 109-112 12767058-5 2003 The induction of p53 (3 hr) precedes the induction of NAG-1 (12 hr), suggesting that genistein-induced NAG-1 expression is mediated by p53. Genistein 85-94 tumor protein p53 Homo sapiens 17-20 12767058-5 2003 The induction of p53 (3 hr) precedes the induction of NAG-1 (12 hr), suggesting that genistein-induced NAG-1 expression is mediated by p53. Genistein 85-94 tumor protein p53 Homo sapiens 135-138 12767058-8 2003 The expression of p53 was critical for NAG-1 promoter activity since no promoter activity was observed with genistein treatment in HCT-15 cells. Genistein 108-117 tumor protein p53 Homo sapiens 18-21 12767058-9 2003 However, genistein-induced promoter activity was restored in HCT-15 cells by transfection with wild-type p53. Genistein 9-18 tumor protein p53 Homo sapiens 105-108 12767922-2 2003 Here we show that topoisomerase II inhibitors, genistein and etoposide, induce p21(WAF1/Cip1) expression mainly in a p53-dependent manner in human lung cancer cell line A549. Genistein 47-56 tumor protein p53 Homo sapiens 117-120 14757171-7 2004 Caffeine, an ATM kinase inhibitor, inhibited these effects of genistein on Chk2, p53, and p21waf1/cip1. Genistein 62-71 tumor protein p53 Homo sapiens 81-84 12767922-6 2003 These data suggest that both genistein and etoposide induce p21(WAF1/Cip1) expression in a p53-dependent manner. Genistein 29-38 tumor protein p53 Homo sapiens 91-94 12767922-7 2003 Genistein appears to stimulate p21(WAF1/Cip1) expression through p53 via ATM, whereas etoposide may activate both ATM and ATR pathways. Genistein 0-9 tumor protein p53 Homo sapiens 65-68 12793003-2 2003 Western Blot was used to detect the changes of the expression of p53 protein, Caspase-3 after SGC-7901 cells were exposed to genistein. Genistein 125-134 tumor protein p53 Homo sapiens 65-68 11316564-6 2001 In terms of changes in expression of p53-related proteins, increase in expression of Bax and decrease in that of Bcl-2 were observed in TE-2 but not in TE-1, suggesting that the main mode of cell death induced by genistein in a cell line with wild type p53 differed from that with mutant p53. Genistein 213-222 tumor protein p53 Homo sapiens 253-256 11316564-6 2001 In terms of changes in expression of p53-related proteins, increase in expression of Bax and decrease in that of Bcl-2 were observed in TE-2 but not in TE-1, suggesting that the main mode of cell death induced by genistein in a cell line with wild type p53 differed from that with mutant p53. Genistein 213-222 tumor protein p53 Homo sapiens 253-256 11286989-5 2001 In addition, genistein enhanced the expression of the cell cycle inhibitor p21(waf/cip1) by 10- to 15-fold, increased p21(waf/cip1) association with Cdc2 by 2-fold, and increased the expression of the tumor suppressor p53 by 2.8-fold. Genistein 13-22 tumor protein p53 Homo sapiens 218-221 11295047-2 2001 A block of cell cycle checkpoint by dexamethasone and genistein correlates with a selective induction of cyclin-dependent kinase (Cdk) inhibitor p21WAF1/CIP1 in a tumor suppressor p53-independent manner and abolishment of Cdk2 phosphorylation. Genistein 54-63 tumor protein p53 Homo sapiens 180-183 10529369-1 1999 Overexpression of the tumor suppressor p53 in HeLa cells leads to loss of the estradiol- and genistein-induced human estrogen receptor (ERalpha) transactivity. Genistein 93-102 tumor protein p53 Homo sapiens 39-42 11400165-6 2001 In elucidating these findings, it was determined that after 2 days of incubation with genistein, MCF-7 but not MDA-MB-231 cells, had significantly higher levels of p53. Genistein 86-95 tumor protein p53 Homo sapiens 164-167 11400165-8 2001 Levels of p21 increased in both of the genistein-treated cell lines, suggesting that p21 gene expression was activated but in a p53-independent manner, whereas no significant changes in levels of the pro-apoptotic protein, Bax, were found. Genistein 39-48 tumor protein p53 Homo sapiens 128-131 11096068-5 2001 Here we show that genistein induces the up-regulation of p53 protein, phosphorylation of p53 at serine 15, activation of the sequence-specific DNA binding properties of p53, and phosphorylation of the hCds1/Chk2 protein kinase at threonine 68. Genistein 18-27 tumor protein p53 Homo sapiens 57-60 11096068-5 2001 Here we show that genistein induces the up-regulation of p53 protein, phosphorylation of p53 at serine 15, activation of the sequence-specific DNA binding properties of p53, and phosphorylation of the hCds1/Chk2 protein kinase at threonine 68. Genistein 18-27 tumor protein p53 Homo sapiens 89-92 11096068-5 2001 Here we show that genistein induces the up-regulation of p53 protein, phosphorylation of p53 at serine 15, activation of the sequence-specific DNA binding properties of p53, and phosphorylation of the hCds1/Chk2 protein kinase at threonine 68. Genistein 18-27 tumor protein p53 Homo sapiens 89-92 11096068-9 2001 Together our data suggest that ATM is required for activation of a DNA damage-induced pathway that activates p53 and Chk2 in response to genistein. Genistein 137-146 tumor protein p53 Homo sapiens 109-112 10761703-7 2000 Genistein also induced the activation of a p21 promoter reporter construct, utilizing a sequence distinct from the p53-binding site. Genistein 0-9 tumor protein p53 Homo sapiens 115-118 10761703-3 2000 In the present study, we have addressed the mechanism of action by which genistein suppressed the proliferation of p53-null human prostate carcinoma cells. Genistein 73-82 tumor protein p53 Homo sapiens 115-118 10761703-5 2000 The inhibitory effects of genistein on cell growth proliferation were associated with a G2/M arrest in cell cycle progression concomitant with a marked inhibition of cyclin B1 and an induction of Cdk inhibitor p21 (WAF1/CIP1) in a p53-independent manner. Genistein 26-35 tumor protein p53 Homo sapiens 231-234 10427135-3 1999 We have previously shown that genistein inhibits the growth of MDA-MB-231 breast cancer cells, regulates the expression of apoptosis-related genes, and induces apoptosis through a p53-independent pathway. Genistein 30-39 tumor protein p53 Homo sapiens 180-183 10368806-9 1999 Furthermore, cells treated with genistein showed an increased expression of endogenous wild-type p53, while the level of the mutant p53 protein remained unchanged. Genistein 32-41 tumor protein p53 Homo sapiens 97-100 11776565-4 1999 RESULTS: Genistein could inhibit proliferation of human breast carcinoma cells with different ER status and p53 status. Genistein 9-18 tumor protein p53 Homo sapiens 108-111 11776565-8 1999 CONCLUSION: The inhibitory effect of genistein on cell proliferation of breast cancer appears to be due to p21WAF1/CIP1 expression and apoptosis through mechanism independent of ER and p53. Genistein 37-46 tumor protein p53 Homo sapiens 185-188 10340389-7 1999 From these results, we conclude that genistein inhibits the growth of MDA-MB-231 breast cancer cells, regulates the expression of apoptosis-related genes, and induces apoptosis through a p53-independent pathway. Genistein 37-46 tumor protein p53 Homo sapiens 187-190 10368806-10 1999 From these results, we conclude that genistein induces apoptosis in NSCLC cells through a p53-independent pathway and, thus, may act as an anticancer agent. Genistein 37-46 tumor protein p53 Homo sapiens 90-93 8829621-3 1996 On the other hand, significant induction of p53 message was demonstrated when Hela cells were exposed to genistein, a protein tyrosine kinase inhibitor. Genistein 105-114 tumor protein p53 Homo sapiens 44-47 9513045-6 1998 The similar effects of genistein on a number of breast carcinoma cell lines with different ER and p53 status suggest that the actions of genistein reported here are mediated through ER and p53 independent mechanisms. Genistein 137-146 tumor protein p53 Homo sapiens 98-101 9513045-6 1998 The similar effects of genistein on a number of breast carcinoma cell lines with different ER and p53 status suggest that the actions of genistein reported here are mediated through ER and p53 independent mechanisms. Genistein 137-146 tumor protein p53 Homo sapiens 189-192 9184169-5 1997 Further support for this observation came from the stable transfection studies in which p53 transfectants expressing high levels of wild-type p53 became resistant to genistein. Genistein 166-175 tumor protein p53 Homo sapiens 88-91 9184169-5 1997 Further support for this observation came from the stable transfection studies in which p53 transfectants expressing high levels of wild-type p53 became resistant to genistein. Genistein 166-175 tumor protein p53 Homo sapiens 142-145 10023317-4 1998 At 0.15 mM, genistein caused an increase in the steady-state levels of the wild-type tumour suppressor p53, which was attributed to stabilising the tumour suppressor protein, since p53 mRNA levels did not increase. Genistein 12-21 tumor protein p53 Homo sapiens 103-106